These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28074560)

  • 1. Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT
    Álvarez-Román MT; Fernandez-Bello I; de la Corte-Rodríguez H; Hernández-Moreno AL; Martín-Salces M; Butta-Coll N; Rivas-Pollmar MI; Rivas-Muñoz S; Jiménez-Yuste V
    Haemophilia; 2017 Jan; 23(1):e50-e54. PubMed ID: 28074560
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT
    Mingot-Castellano ME; Parra R; Núñez R; Martorell M
    Haemophilia; 2018 Sep; 24(5):e338-e343. PubMed ID: 30028549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Savings without changing: How to use the MyPKfit® device to improve treatment strategies in a cohort of patients with haemophilia A.
    Pasca S; Zanon E
    Thromb Res; 2019 Nov; 183():1-3. PubMed ID: 31505377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A.
    Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Monte E; Pérez-Alenda S; Bosch P; Querol F; Poveda JL
    Thromb Res; 2019 Feb; 174():151-162. PubMed ID: 30634166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa.
    Arvanitakis A; Berntorp E; Astermark J
    Haemophilia; 2021 May; 27(3):417-424. PubMed ID: 33751755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic model for factor VIII dosing during active haemorrhage in patients with haemophilia A.
    Ho AM; Dion P; Karmakar MK; Cheng G; Derrick JL; Chung DC; Tay BA
    Anaesthesia; 2001 Aug; 56(8):785-90. PubMed ID: 11493246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. North-eastern Brazilian recommendations for the nurse professional role on the pharmacokinetic-assisted prophylaxis individualization for haemophilia A.
    de Morais Costa NC; Costa ÍM; Guimarães TMR; de Souza HP; Casaretto ES; de Medeiros TC; Barbosa SM; Matos AIEL; Oliveira EG; Camelo RM
    Haemophilia; 2020 May; 26(3):e120-e123. PubMed ID: 32026514
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A.
    Steele MR; Nagel K; Chan AK
    Haemophilia; 2014 Jan; 20(1):e100-1. PubMed ID: 24251412
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to Gringeri et al.: 'Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling'.
    Shapiro AD; Li S
    Haemophilia; 2015 Nov; 21(6):e489-92. PubMed ID: 26173031
    [No Abstract]   [Full Text] [Related]  

  • 10. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis in patients with haemophilia: introduction.
    Chambost H
    Haemophilia; 2010 Mar; 16 Suppl 2():1-3. PubMed ID: 20132331
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prediction of Coagulation Factor Ⅷ Level in Chinese Hemophilia A Patients by the Pharmacokinetic Management Tool myPKFiT].
    Hua BL; Xiao J; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Apr; 45(2):200-205. PubMed ID: 37157065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemostatic response to factor VIII administration in patients with haemophilia A measured by thrombin generation and correlation with factor concentrate use.
    Hugenholtz GC; Luddington R; Baglin T
    Haemophilia; 2016 Jan; 22(1):e42-5. PubMed ID: 26388112
    [No Abstract]   [Full Text] [Related]  

  • 15. Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A.
    Ragni MV; Yabes JG; Fogarty PF; Josephson NC; Kessler CM; Neff AT; Raffini L; Brummel-Ziedins K; Moore CG
    Haemophilia; 2017 Jan; 23(1):e43-e46. PubMed ID: 27943502
    [No Abstract]   [Full Text] [Related]  

  • 16. Experience with highly purified porcine factor VIII in a patient with haemophilia A and a factor VIII inhibitor.
    Colvin BT; Ainsworth M; Buckley C
    Clin Lab Haematol; 1983; 5(1):55-9. PubMed ID: 6406130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A.
    Kremer Hovinga ICL; Schutgens REG; van der Valk PR; van Vulpen LFD; Mauser-Bunschoten EP; Fischer K
    Haemophilia; 2018 Jul; 24(4):e280-e283. PubMed ID: 30044044
    [No Abstract]   [Full Text] [Related]  

  • 18. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials.
    Fischer K; Collins P; Björkman S; Blanchette V; Oh M; Fritsch S; Schroth P; Spotts G; Ewenstein B
    Haemophilia; 2011 May; 17(3):433-8. PubMed ID: 21299740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly purified porcine factor VIII in haemophilia A with inhibitors to factor VIII.
    Mayne EE; Madden M; Crothers IS; Ingles T
    Br Med J (Clin Res Ed); 1981 Jan; 282(6260):318. PubMed ID: 6780009
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII.
    Kempton CL; Meeks SL; Donald Harvey R; Abshire TC
    Haemophilia; 2011 Jan; 17(1):155-6. PubMed ID: 20579112
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.